FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140402067> ?p ?o ?g. }

• W2140402067 endingPage "203" @default.
• W2140402067 startingPage "196" @default.
• W2140402067 abstract "Purpose Richter's syndrome (RS) and fludarabine-refractory chronic lymphocytic leukemia (CLL) are associated with poor clinical outcomes. We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases. Patients and Methods The OFAR regimen consisted of increasing doses of oxaliplatin (17.5, 20, or 25 mg/m 2 /d) on days 1 to 4 (phase I), fludarabine 30 mg/m 2 on days 2 to 3, cytarabine 1 g/m 2 on days 2 to 3, rituximab 375 mg/m 2 on day 3 of cycle 1 and day 1 of subsequent cycles, and pegfilgrastim 6 mg on day 6, every 4 weeks for a maximum of six courses. Dose-limiting toxicity (DLT) was defined as any nonhematologic, treatment-related toxicity ≥ grade 3. Results Fifty patients were treated (20 patients had RS, and 30 had CLL). The highest tolerated oxaliplatin dose was 25 mg/m 2 , which was the highest dose tested. DLT was not observed. Pharmacodynamic analyses demonstrated enhanced leukemia cell killing by oxaliplatin in the presence of fludarabine and cytarabine. The overall response rates were 50% in RS and 33% in fludarabine-refractory CLL. The overall response rate in 14 patients with age ≥ 70 years was 50%. Responses were achieved in seven (35%) of 20 patients with 17p deletion, two (29%) of seven patients with 11q deletion, all four patients with trisomy 12, and two (40%) of five patients with 13q deletion. The median response duration was 10 months. Toxicities were mainly hematologic; prolonged myelosuppression was not observed. Conclusion The OFAR regimen is highly active in RS and has activity in fludarabine-refractory patients with CLL. This regimen warrants further investigation in the treatment of these disorders." @default.
• W2140402067 created "2016-06-24" @default.
• W2140402067 creator A5006104041 @default.
• W2140402067 creator A5016570475 @default.
• W2140402067 creator A5027575595 @default.
• W2140402067 creator A5028845635 @default.
• W2140402067 creator A5035354255 @default.
• W2140402067 creator A5036290225 @default.
• W2140402067 creator A5036828560 @default.
• W2140402067 creator A5040146877 @default.
• W2140402067 creator A5044840107 @default.
• W2140402067 creator A5045902951 @default.
• W2140402067 creator A5050284072 @default.
• W2140402067 creator A5053481267 @default.
• W2140402067 creator A5061026876 @default.
• W2140402067 creator A5084290698 @default.
• W2140402067 creator A5089428686 @default.
• W2140402067 creator A5090435894 @default.
• W2140402067 date "2008-01-10" @default.
• W2140402067 modified "2023-10-15" @default.
• W2140402067 title "Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia" @default.
• W2140402067 cites W146673805 @default.
• W2140402067 cites W1880372716 @default.
• W2140402067 cites W1881397173 @default.
• W2140402067 cites W1912693401 @default.
• W2140402067 cites W1963690972 @default.
• W2140402067 cites W1985871504 @default.
• W2140402067 cites W2016333491 @default.
• W2140402067 cites W2019537425 @default.
• W2140402067 cites W2032171886 @default.
• W2140402067 cites W2032553799 @default.
• W2140402067 cites W2047259755 @default.
• W2140402067 cites W2051667118 @default.
• W2140402067 cites W2053856343 @default.
• W2140402067 cites W2055386018 @default.
• W2140402067 cites W2058015212 @default.
• W2140402067 cites W2061000716 @default.
• W2140402067 cites W2066136548 @default.
• W2140402067 cites W2069901281 @default.
• W2140402067 cites W2087824134 @default.
• W2140402067 cites W2094603195 @default.
• W2140402067 cites W2110098454 @default.
• W2140402067 cites W2117648265 @default.
• W2140402067 cites W2122567519 @default.
• W2140402067 cites W2123133140 @default.
• W2140402067 cites W2125134816 @default.
• W2140402067 cites W2128655114 @default.
• W2140402067 cites W2129869923 @default.
• W2140402067 cites W2130081091 @default.
• W2140402067 cites W2136629418 @default.
• W2140402067 cites W2137804513 @default.
• W2140402067 cites W2159880472 @default.
• W2140402067 cites W2171232394 @default.
• W2140402067 cites W2326175431 @default.
• W2140402067 cites W4237443037 @default.
• W2140402067 cites W60865865 @default.
• W2140402067 cites W96780237 @default.
• W2140402067 doi "https://doi.org/10.1200/jco.2007.11.8513" @default.
• W2140402067 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18182662" @default.
• W2140402067 hasPublicationYear "2008" @default.
• W2140402067 type Work @default.
• W2140402067 sameAs 2140402067 @default.
• W2140402067 citedByCount "140" @default.
• W2140402067 countsByYear W21404020672012 @default.
• W2140402067 countsByYear W21404020672013 @default.
• W2140402067 countsByYear W21404020672014 @default.
• W2140402067 countsByYear W21404020672015 @default.
• W2140402067 countsByYear W21404020672016 @default.
• W2140402067 countsByYear W21404020672017 @default.
• W2140402067 countsByYear W21404020672018 @default.
• W2140402067 countsByYear W21404020672019 @default.
• W2140402067 countsByYear W21404020672020 @default.
• W2140402067 countsByYear W21404020672021 @default.
• W2140402067 countsByYear W21404020672022 @default.
• W2140402067 countsByYear W21404020672023 @default.
• W2140402067 crossrefType "journal-article" @default.
• W2140402067 hasAuthorship W2140402067A5006104041 @default.
• W2140402067 hasAuthorship W2140402067A5016570475 @default.
• W2140402067 hasAuthorship W2140402067A5027575595 @default.
• W2140402067 hasAuthorship W2140402067A5028845635 @default.
• W2140402067 hasAuthorship W2140402067A5035354255 @default.
• W2140402067 hasAuthorship W2140402067A5036290225 @default.
• W2140402067 hasAuthorship W2140402067A5036828560 @default.
• W2140402067 hasAuthorship W2140402067A5040146877 @default.
• W2140402067 hasAuthorship W2140402067A5044840107 @default.
• W2140402067 hasAuthorship W2140402067A5045902951 @default.
• W2140402067 hasAuthorship W2140402067A5050284072 @default.
• W2140402067 hasAuthorship W2140402067A5053481267 @default.
• W2140402067 hasAuthorship W2140402067A5061026876 @default.
• W2140402067 hasAuthorship W2140402067A5084290698 @default.
• W2140402067 hasAuthorship W2140402067A5089428686 @default.
• W2140402067 hasAuthorship W2140402067A5090435894 @default.
• W2140402067 hasBestOaLocation W21404020671 @default.
• W2140402067 hasConcept C121332964 @default.
• W2140402067 hasConcept C121608353 @default.
• W2140402067 hasConcept C126322002 @default.
• W2140402067 hasConcept C142424586 @default.
• W2140402067 hasConcept C143998085 @default.

• next